Astragaloside IV Alleviates Liver Inflammation, Oxidative Stress and Apoptosis to Protect Against Experimental Non-Alcoholic Fatty Liver Disease

Xiao-yu Liang,1 Fen-Fang Hong,2 Shu-Long Yang1 1Department of Physiology, College of Medicine, Nanchang University, Nanchang, 330006, People’s Republic of China; 2Experimental Teaching Center, Nanchang University, Nanchang, 330031, People’s Republic of ChinaCorrespondence: Shu-Lo...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Liang XY, Hong Ff, Yang SL
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2021
Sujets:	astragaloside iv non-alcoholic fatty liver disease lipid accumulation oxidative stress apoptosis. Specialties of internal medicine RC581-951
Accès en ligne:	https://doaj.org/article/9c04d24d1f844b5e9681e2b6a9c1f542
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

id	oai:doaj.org-article:9c04d24d1f844b5e9681e2b6a9c1f542
record_format	dspace
spelling	oai:doaj.org-article:9c04d24d1f844b5e9681e2b6a9c1f5422021-12-02T14:51:56ZAstragaloside IV Alleviates Liver Inflammation, Oxidative Stress and Apoptosis to Protect Against Experimental Non-Alcoholic Fatty Liver Disease1178-7007https://doaj.org/article/9c04d24d1f844b5e9681e2b6a9c1f5422021-04-01T00:00:00Zhttps://www.dovepress.com/astragaloside-iv-alleviates-liver-inflammation-oxidative-stress-and-ap-peer-reviewed-fulltext-article-DMSOhttps://doaj.org/toc/1178-7007Xiao-yu Liang,1 Fen-Fang Hong,2 Shu-Long Yang1 1Department of Physiology, College of Medicine, Nanchang University, Nanchang, 330006, People’s Republic of China; 2Experimental Teaching Center, Nanchang University, Nanchang, 330031, People’s Republic of ChinaCorrespondence: Shu-Long YangDepartment of Physiology, College of Medicine, Nanchang University, Nanchang, 330006, People’s Republic of ChinaTel +86 13576291532Email slyang@ncu.edu.cnFen-Fang HongExperimental Teaching Center, Nanchang University, Nanchang, 330031, People’s Republic of ChinaTel +86 18970965319Email hongfenfang@126.comPurpose: Non-alcoholic fatty liver disease (NAFLD) is the main form of chronic liver disease in the world. Astragaloside IV (ASIV) has been tested in experimental models of different diseases. The purpose of this study was to evaluate the effect and protective mechanism of ASIV on NAFLD.Methods: Lipopolysaccharide (LPS)- and palmitate acid (PA)-induced RAW264.7 cells and LO2 cells were used as a NAFLD model. The mice NAFLD model was evaluated by hematoxylin-eosin staining (HE staining), and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels. Liver lipid metabolism was evaluated by triglyceride (TG) and total cholesterol (TC) kits and oil red O staining. Oxidative stress indicators were examined through biochemical methods. Inflammatory factors were explored through enzyme-linked immuno sorbent assay (ELISA), real-time quantitative PCR and oxidative stress indicator kits. The expression levels of 5-LO (5-lipoxygenase) and leukotriene A4 hydrolase (LTA4H) were checked by real-time quantitative PCR and Western blotting. Apoptosis was detected by Annexin V-FITC/PI cell apoptosis detection kit.Results: Our results showed that in vivo ASIV significantly reduced liver tissue damage, and serum AST, ALT and serum TG levels in NAFLD mice. In vitro, ASIV reduced cell supernatant TG and TC content increased by PA treatment, and significantly decreased the accumulation of intracellular lipid droplets induced by PA treatment. Additionally, ASIV reduced reactive oxygen species (ROS) and malondialdehyde (MDA) levels, and restored glutathione peroxidase (GSH-Px) levels in PA-treated LO2 cell supernatant. Furthermore, ASIV inhibited the production of proinflammatory cytokines (IL-6 and TNF-α) in RAW264.7 cells induced by LPS. We also found that ASIV downregulated the expression of 5-LO and LTB4 (leukotriene B4) in NAFLD mice. Moreover, ASIV restored apoptotic protein (Bax and Bcl-2) expression in PA-treated LO2 cells.Conclusion: ASIV may reduce liver steatosis, hepatocyte oxidative stress and apoptosis, and decrease liver inflammation, thereby attenuating the progression of NAFLD and thus might be of therapeutic interest.Keywords: astragaloside IV, non-alcoholic fatty liver disease, lipid accumulation, oxidative stress, apoptosisLiang XYHong FfYang SLDove Medical Pressarticleastragaloside ivnon-alcoholic fatty liver diseaselipid accumulationoxidative stressapoptosis.Specialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 14, Pp 1871-1883 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	astragaloside iv non-alcoholic fatty liver disease lipid accumulation oxidative stress apoptosis. Specialties of internal medicine RC581-951
spellingShingle	astragaloside iv non-alcoholic fatty liver disease lipid accumulation oxidative stress apoptosis. Specialties of internal medicine RC581-951 Liang XY Hong Ff Yang SL Astragaloside IV Alleviates Liver Inflammation, Oxidative Stress and Apoptosis to Protect Against Experimental Non-Alcoholic Fatty Liver Disease
description	Xiao-yu Liang,1 Fen-Fang Hong,2 Shu-Long Yang1 1Department of Physiology, College of Medicine, Nanchang University, Nanchang, 330006, People’s Republic of China; 2Experimental Teaching Center, Nanchang University, Nanchang, 330031, People’s Republic of ChinaCorrespondence: Shu-Long YangDepartment of Physiology, College of Medicine, Nanchang University, Nanchang, 330006, People’s Republic of ChinaTel +86 13576291532Email slyang@ncu.edu.cnFen-Fang HongExperimental Teaching Center, Nanchang University, Nanchang, 330031, People’s Republic of ChinaTel +86 18970965319Email hongfenfang@126.comPurpose: Non-alcoholic fatty liver disease (NAFLD) is the main form of chronic liver disease in the world. Astragaloside IV (ASIV) has been tested in experimental models of different diseases. The purpose of this study was to evaluate the effect and protective mechanism of ASIV on NAFLD.Methods: Lipopolysaccharide (LPS)- and palmitate acid (PA)-induced RAW264.7 cells and LO2 cells were used as a NAFLD model. The mice NAFLD model was evaluated by hematoxylin-eosin staining (HE staining), and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels. Liver lipid metabolism was evaluated by triglyceride (TG) and total cholesterol (TC) kits and oil red O staining. Oxidative stress indicators were examined through biochemical methods. Inflammatory factors were explored through enzyme-linked immuno sorbent assay (ELISA), real-time quantitative PCR and oxidative stress indicator kits. The expression levels of 5-LO (5-lipoxygenase) and leukotriene A4 hydrolase (LTA4H) were checked by real-time quantitative PCR and Western blotting. Apoptosis was detected by Annexin V-FITC/PI cell apoptosis detection kit.Results: Our results showed that in vivo ASIV significantly reduced liver tissue damage, and serum AST, ALT and serum TG levels in NAFLD mice. In vitro, ASIV reduced cell supernatant TG and TC content increased by PA treatment, and significantly decreased the accumulation of intracellular lipid droplets induced by PA treatment. Additionally, ASIV reduced reactive oxygen species (ROS) and malondialdehyde (MDA) levels, and restored glutathione peroxidase (GSH-Px) levels in PA-treated LO2 cell supernatant. Furthermore, ASIV inhibited the production of proinflammatory cytokines (IL-6 and TNF-α) in RAW264.7 cells induced by LPS. We also found that ASIV downregulated the expression of 5-LO and LTB4 (leukotriene B4) in NAFLD mice. Moreover, ASIV restored apoptotic protein (Bax and Bcl-2) expression in PA-treated LO2 cells.Conclusion: ASIV may reduce liver steatosis, hepatocyte oxidative stress and apoptosis, and decrease liver inflammation, thereby attenuating the progression of NAFLD and thus might be of therapeutic interest.Keywords: astragaloside IV, non-alcoholic fatty liver disease, lipid accumulation, oxidative stress, apoptosis
format	article
author	Liang XY Hong Ff Yang SL
author_facet	Liang XY Hong Ff Yang SL
author_sort	Liang XY
title	Astragaloside IV Alleviates Liver Inflammation, Oxidative Stress and Apoptosis to Protect Against Experimental Non-Alcoholic Fatty Liver Disease
title_short	Astragaloside IV Alleviates Liver Inflammation, Oxidative Stress and Apoptosis to Protect Against Experimental Non-Alcoholic Fatty Liver Disease
title_full	Astragaloside IV Alleviates Liver Inflammation, Oxidative Stress and Apoptosis to Protect Against Experimental Non-Alcoholic Fatty Liver Disease
title_fullStr	Astragaloside IV Alleviates Liver Inflammation, Oxidative Stress and Apoptosis to Protect Against Experimental Non-Alcoholic Fatty Liver Disease
title_full_unstemmed	Astragaloside IV Alleviates Liver Inflammation, Oxidative Stress and Apoptosis to Protect Against Experimental Non-Alcoholic Fatty Liver Disease
title_sort	astragaloside iv alleviates liver inflammation, oxidative stress and apoptosis to protect against experimental non-alcoholic fatty liver disease
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/9c04d24d1f844b5e9681e2b6a9c1f542
work_keys_str_mv	AT liangxy astragalosideivalleviatesliverinflammationoxidativestressandapoptosistoprotectagainstexperimentalnonalcoholicfattyliverdisease AT hongff astragalosideivalleviatesliverinflammationoxidativestressandapoptosistoprotectagainstexperimentalnonalcoholicfattyliverdisease AT yangsl astragalosideivalleviatesliverinflammationoxidativestressandapoptosistoprotectagainstexperimentalnonalcoholicfattyliverdisease
_version_	1718389462797385728

Astragaloside IV Alleviates Liver Inflammation, Oxidative Stress and Apoptosis to Protect Against Experimental Non-Alcoholic Fatty Liver Disease

Documents similaires